Estimated annual leak · modeled range
$0a year
Modeled midpoint, prorated. Not a measured loss.
Pharma · margin leak estimator
How much is your Pharma marketing leaking?
Use your revenue, marketing spend and answers to explore a modeled annual opportunity range. Free, with no login or account access.
Use the results on your own, or choose a paid audit or a fit call. Both next steps are optional.
Free · No login · Nothing leaves your browser
Model reference: $64k/yr. Published cases: 9, lower median $64,000/yr. Prescription products, diagnostics, consumer health and devices have different demand paths and constraints. The combined model cannot establish segment specific conversion or commercial outcomes.
Live reading · updates on every answer
Leak risk score
Appears after your first answer. Based on your answers, not on the dollars.
Pick an industry to sharpen the range.
Directional model output. Not a measured loss or promised recovery. Formula and rates are disclosed below.
Step 1 of 7 · Tell us about the Pharma business
Rough numbers are fine.
Tell us about the Pharma business
Three quick inputs set your baseline. Rough numbers are fine, and nothing leaves your browser.
Quick start
Industry
Advanced: blended ROAS and site conversion rate (optional)
Optional, and it stays in your browser. Either number narrows your range instead of widening it: the model stops guessing at your efficiency and uses yours.
Choice steps advance on click. Nothing leaves your browser.
In their words · 8 Pharma client statementsAll 60 client statements →
PHARMA
$88k annual budget redirection identified in 7 days
Congress spend with a tracked return: 8% → 88%
“Six figures a year in congresses and KOL sponsorships, renewed on habit. Leslie tried to connect it to share of voice, engagement or prescribing and found no instrumentation at all. The unmeasurable part now funds engagement we can track.”
Head of Commercial Strategy · Pharma · Biopharma
Written approvalUnder NDA7 days to findings
Leslie MartinSenior Auditor · signed this audit offPHARMA
$78k a year of wasted spend cut in 7 days
High intent visitors paid for twice: ~1 in 3 → ~1 in 30
“Two teams, two search programs, one visitor bought twice. Leslie looked at branded and disease awareness search together for the first time: about one high intent visitor in three was paid for twice. Shared negatives and one plan ended it.”
VP of Marketing · Pharma · Rx brand (DTC)
Written approvalUnder NDA7 days to findings
Leslie MartinSenior Auditor · signed this audit offPHARMA
$71k a year of wasted spend cut in 7 days
Acquisition cost vs reimbursement per test: 122% → 78%
“Acquisition and reimbursement sat with different teams, so nobody compared them. Cristian reconciled cost per patient against reimbursement per test: several high volume tests lost money on every patient we marketed in. We capped those.”
CFO · Pharma · Diagnostics
Written approvalUnder NDA7 days to findings
Cristian BragauSenior Auditor · signed this audit offPHARMA
$64k a year of wasted spend cut in 7 days
Detailing spend that moved no prescribing: 28% → 4%
“Reach and call counts looked healthy. Leslie matched detailing and samples to prescribing change per HCP, and 28% of the effort landed on physicians it never moved. Field time now follows responsiveness, not coverage targets.”
Head of Commercial Operations · Pharma · Generics
Written approvalUnder NDA7 days to findings
Leslie MartinSenior Auditor · signed this audit offPHARMA
$64k a year of wasted spend cut in 6 days
Budget lost to the two teams overbidding: 22% → 3%
“Our HCP and patient agencies were bidding against each other for the same impressions. Cristian examined both programs together for the first time and merged audience planning. Reach held, and the internal premium was gone.”
Director of Commercial Operations · Pharma · Medtech / device
Written approvalUnder NDA6 days to findings
Cristian BragauSenior Auditor · signed this audit offPHARMA
+26% media efficiency in 7 days
Media weight landing in real demand windows: 45% → 88%
“Our flighting calendar was older than our customers' habits. Cristian compared spend timing against when the category actually converts: our heaviest weight landed in weak windows. Same budget, real demand windows, efficiency up 26%.”
Brand Director · Pharma · OTC consumer health
Written approvalUnder NDA7 days to findings
Cristian BragauSenior Auditor · signed this audit offPHARMA
$58k a year of wasted spend cut in 6 days
Media spend outside eligible patient windows: 24% → 2%
“Reach looked healthy, but a quarter of our media reached people who could not act on it. Leslie compared delivery against the eligible population and its windows: 24% of spend fell outside them. Flighting now follows eligibility.”
Brand Director · Pharma · Vaccines
Written approvalUnder NDA6 days to findings
Leslie MartinSenior Auditor · signed this audit offPHARMA
$49k a year found in 6 days
Margin on the thin vet channel lines: −2% → +5%
“One discount for the whole range looked competitive. Leslie checked it against margin by product line, and on our thinner lines it pushed them below cost. Discount tiers now follow margin band, and the channel kept its competitive pricing.”
Director of Commercial Channels · Pharma · Animal health
Written approvalUnder NDA6 days to findings
Leslie MartinSenior Auditor · signed this audit offThe calculator is free. An optional paid audit checks your account data and produces evidence for its findings.
What is the next step?
Keep your estimate, explore the case studies or request a paid audit. The calculator does not connect to your accounts. A fit call can help you assess whether an audit is appropriate.
Model assumptions and limitations
This calculator applies model assumptions to your inputs. Its range, comparison position and score are directional scenarios, not measured account losses, verified peer percentiles or a recovery promise. The industry reference amounts are model references, distinct from the lower medians of published case figures. Underlying calibration budgets and validation evidence are not published.
- Monthly marketing spend is multiplied by 12 and the selected industry rate band. Monthly revenue is multiplied by 12 and 0.84% to 1.63% for the second term. These two modeled terms are added, adjusted by your answers, and rounded.
- Higher spend changes the marketing term; higher revenue changes the pricing, margin and retention term. These terms may describe related economic effects, so their sum is a scenario for investigation, not additive proven savings.
- The comparison uses the marketing term only. Its reference is annual marketing spend multiplied by the middle point of the industry model curve. A position from 10 to 90 on that curve is not an observed peer percentile.
- The 0 to 100 score summarizes the selected answers. Category scores reflect allocated shares of the estimated midpoint, not independently measured health.
- Optional ROAS and conversion inputs scale the range against model reference values and narrow it by a fixed factor of 0.70 before rounding. A narrower interval does not establish greater statistical confidence.
- When spend exceeds half of revenue, a midpoint limit of 6% of annual revenue can activate. Rounding and minimum interval width still apply. This is a model safeguard, not an observed business limit.
Input and coefficient sensitivity are model behavior. Calibration periods, eligible budgets and validation errors are unavailable in the published cases.
Directional model estimates, not a diagnosis of your accounts. Nothing leaves your browser to produce this result.
Behind the Pharma estimate
What the model assumes for Pharma
The Pharma model reference is $64k a year. Among the five modeled categories, Pharma gives Attribution & tracking a 15% heavier weight in the category split and a head start as the first area to investigate when your answers point two ways.
The 9 published Pharma cases are a separate statistic: a lower median annual highlight figure of $64,000, computed from the cases listed below, not from the model. The largest of them is Congress and KOL sponsorship showed no measurable return, $88k a year, found in 7 days.
What the Pharma estimator asks
Every version of the calculator starts from monthly revenue and monthly marketing spend. Three of the seven questions then carry Pharma options, listed here as the wizard shows them. Each option still maps to the same five leak categories, which is what keeps a Pharma estimate comparable with any other.
Where does most of your marketing budget go?
The Pharma channel mix. The answer moves weight between wasted paid spend and attribution.
- HCP digital media: Programmatic, endemic sites & triggered email
- KOL & field programs: Speaker programs, ad boards, field activity
- Congresses & events
- DTC / patient media
- Honestly, I’m not sure
How do you mainly make money?
The Pharma revenue model. The answer moves weight between pricing and retention.
- Prescription / script volume
- Payer / tender contracts: Formulary access, tenders & rebates
- OTC / retail sales
- A mix
- Not sure / it varies
Where do you suspect you lose the most?
The Pharma vocabulary for the five categories. The answer orders the checklist; it never moves the score.
- Tracked return on congress / KOL spend
- HCP / DTC media efficiency
- Engagement to script conversion
- Access & contract pricing
- HCP relationships & renewals
- Not sure: that’s why I’m here
Tracking and the optional inputs
Pharma answers the tracking question on a CRM scale: CRM matched, closed loop attribution, CRM + campaign source tracking, Web analytics + CRM, not joined and Spreadsheets & platform reports. Spend there is tied to won revenue, not to a web conversion.
Advanced, optional: a site conversion rate, placeholder 1.0%. The blended ROAS field is hidden for Pharma, where it is not a number the business runs on.
Four Pharma leak patterns from the published cases
Each card names the cases it rests on; open one for its evidence. Together the cards cover all 9 published Pharma cases. The Pharma marketing audit page explains each pattern and shows the before and after of its largest case.
Events and field
Congress, KOL and detailing spend with no tracked return
2 of the 9 published cases · $64k to $88k a year
Media timing
Media weighted outside the windows that convert
2 of the 9 published cases · $58k to $60k a year
Overlap
Budgets bidding against each other
2 of the 9 published cases · $64k to $78k a year
Unit economics
Acquisition and discounts above what they return
3 of the 9 published cases · $44k to $71k a year
- Subscription acquisition ignored regulatory driven churn, +$44k a year
- Retail vet channel discounts were set below margin, +$49k a year
- Patient acquisition spend ran above what reimbursement paid, −$71k a year
What an audit checks after a Pharma estimate
- Congress and KOL spend against tracked engagement outcomes
- HCP digital channel return benchmarking
- Regional and clinic level targeting overlap
- Compliance safe attribution design
- Field and digital engagement cost per interaction
The estimate points at a category; the audit tests these 5 Pharma checks against your own account data. Compare industries in the 2026 benchmark.
Why trust the estimate
A wasted ad spend calculator with explicit assumptions.
01
Industry model assumptions
The calculator uses industry rates and your inputs. Published case lower medians are shown separately so you can compare their definitions.
02
Understand the range
The interval describes a model scenario. It does not establish the percentage of comparable businesses that achieved that result.
03
The audit makes it real
An estimate can’t be acted on by itself. The audit names each leak, proves it with your data and hands you the fix. $10,000 to $50,000 of findings, or your money back.
Next step, optional
Turn estimates into evidence.
Fixed fee. 5 to 7 working days. $10,000 to $50,000 of findings, or your money back.
Questions about the Pharma estimator.
Is the estimator really free, and what’s the catch?
Yes. The Pharma calculator uses your inputs and the Pharma model assumptions, with no account access. You can keep the results or choose an optional paid audit or fit call.
Does the calculator need access to my ad or analytics accounts?
No. It runs entirely in your browser from a few situational inputs, with Pharma preselected as the industry. No logins and no account access, by design.
How accurate is the estimate?
It is a directional model using your inputs and Pharma industry assumptions. Its range and comparison position are not verified peer percentiles or measured account losses. The 9 published Pharma cases are a separate statistic, with a lower median annual highlight figure of $64,000 and a largest published case figure of $88,000 a year. An audit checks your own evidence.
What does the Pharma estimator ask that the general calculator does not?
Three of its seven questions carry Pharma options. Where the budget goes offers HCP digital media, KOL & field programs, Congresses & events and DTC / patient media. How you make money offers Prescription / script volume, Payer / tender contracts, OTC / retail sales and A mix. Where you suspect the loss offers Tracked return on congress / KOL spend, HCP / DTC media efficiency, Engagement to script conversion, Access & contract pricing and HCP relationships & renewals. Each answer still maps to the same five leak categories, so a Pharma estimate is comparable with any other.
Why does the Pharma calculator not ask for a blended ROAS?
Blended ROAS is not a number most Pharma businesses run on, so the Pharma version hides that field and offers one optional input, a site conversion rate with 1.0% as the placeholder. For the same reason its tracking question uses CRM vocabulary, from "CRM matched, closed loop attribution" down to "Spreadsheets & platform reports", instead of the web analytics scale the other industries see.
Pharma wasted ad spend calculator: model and case evidence
This calculator applies model assumptions to your inputs. Its range, comparison position and score are directional scenarios, not measured account losses, verified peer percentiles or a recovery promise. The industry reference amounts are model references, distinct from the lower medians of published case figures. Underlying calibration budgets and validation evidence are not published.
Prescription products, diagnostics, consumer health and devices have different demand paths and constraints. The combined model cannot establish segment specific conversion or commercial outcomes.
Scroll horizontally to compare all columns on a narrow screen.
| Industry | Published cases | Model reference / year | Case lower median / year |
|---|---|---|---|
| Pharma | 9 | $64k | $64,000 |
The population is the 74 published case studies, with one selected highlight figure per case. It is not a representative sample of all SMBs or a total of every finding in each audit. A lower median is the middle value after sorting, using the lower of the two middle values for an even count. Published annual figures include different outcome types; they are not all collected cash, profit or recurring savings. Case publication dates do not establish common observation, implementation or recovery periods; use each case for its supported timing and outcome.